Topoisomerases: A Biochemical Overview
From Proteopedia
Line 33: | Line 33: | ||
== Structural highlights == | == Structural highlights == | ||
- | The primary structure of TOP1 can be divided into three regions. First, the <scene name='91/919047/N-domain/1'>N-domain</scene> contains 214 amino acids, the <scene name='91/919047/Core_region/ | + | The primary structure of TOP1 can be divided into three regions. First, the <scene name='91/919047/N-domain/1'>N-domain</scene> (highlighted in red) contains 214 amino acids, the <scene name='91/919047/Core_region/2'>core region</scene> (highlighted in green) contains 498 amino acids, and the <scene name='91/919047/C-domain/1'>C-domain</scene> (highlighted in purple) contains 114 amino acid residues. [7] |
- | The secondary structure consists of right-handed alpha helices and antiparallel beta strands, which makes up beta sheets. The enzyme consists of 11 alpha helices and 12 beta strands. The clustering of beta sheets in this particular structure of TOP1 creates 3 <scene name='91/919047/B_sheets_highlights/1'>beta sheets</scene>. [7] | + | The secondary structure consists of right-handed alpha helices and antiparallel beta strands, which makes up beta sheets. The enzyme consists of 11 alpha helices and 12 beta strands. The clustering of beta sheets in this particular structure of TOP1 creates 3 <scene name='91/919047/B_sheets_highlights/1'>beta sheets</scene> (highlighted in green). [7] |
The oligomeric state of the quaternary structure is <scene name='91/919047/Space_filling_model/2'>heterotetrameric</scene>. There is no symmetry in this particular enzyme, due to the presence of various distinct subunits. [8] | The oligomeric state of the quaternary structure is <scene name='91/919047/Space_filling_model/2'>heterotetrameric</scene>. There is no symmetry in this particular enzyme, due to the presence of various distinct subunits. [8] | ||
- | The tertiary structure consists of several motifs and domains. The motifs present are alpha bundles, alpha non-bundles, beta rolls, and beta ribbons. The domain consists of five residues of tyrosine and is a loop-like shape. This loop serves as the <scene name='91/919047/Active_site_tyr_723/1'>active site</scene> for the change in conformation, which allows for DNA helices entry. [9] | + | The tertiary structure consists of several motifs and domains. The motifs present are alpha bundles, alpha non-bundles, beta rolls, and beta ribbons. The domain consists of five residues of tyrosine and is a loop-like shape. This loop serves as the <scene name='91/919047/Active_site_tyr_723/1'>active site</scene> (highlighted in purple) for the change in conformation, which allows for DNA helices entry. [9] |
Topoisomerases' structure has hinges that allow it to open and close so it can clamp onto DNA to bind with it. Additionally, it has cavities within it that allow it store DNA segments if needed. Topoisomerase also has a coupling of conformational changes to allow it to make changes in DNA movement and rotation. [10]</StructureSection> | Topoisomerases' structure has hinges that allow it to open and close so it can clamp onto DNA to bind with it. Additionally, it has cavities within it that allow it store DNA segments if needed. Topoisomerase also has a coupling of conformational changes to allow it to make changes in DNA movement and rotation. [10]</StructureSection> |
Revision as of 14:17, 4 March 2023
This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749. |
To get started:
More help: Help:Editing |
Topoisomerase
|
References
1. Natassja G. Bush, Katherine Evans-Roberts, Anthony Maxwell. DNA Topoisomerases. EcoSal Plus (2015), Volume 6, Number 2, Domain: Synthesis and Processing of Macromolecules.
2. Vos, Seychelle M. Tretter, Elsa M. Schmidt, Bryan H. Berger, James M. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. (2011), 12, 12: 827-841.
3. Min Li, Yilun Liu. Topoisomerase I in Human Disease Pathogenesis and Treatments. GPB. (2016), 14, 3: 166-171.
4. Benjamin D. Bax, Garib Murshudov, Anthony Maxwell, Thomas Germe. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion. J. Mol. Biol. (2019), 431, 18: 3427-3449.
5. Seungmin Han, Kwang Suk Lim, Brody J. Blackburn, Jina Yun, Charles W. Putnam, David A. Bull, Young-Wool Won. The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates. Pharmaceutics (2022), 14, 8: 1707-1707.
6. Mei Hong, Ming-Qiang Ren, Jeane Silva, Ananya Paul, W. David Wilson, Carsten Schroeder, Paul Weinberger, John Janik, Zhonglin Hao. YM155 Inhibits Topoisomerase Function. Anticancer Drugs (2017) 28(2): 142-152.
7. Takahashi DT, Gadelle D, Agama K, Kiselev E, Zhang H, Yab E, Petrella S, Forterre P, Pommier Y, Mayer C. Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. Nat. Commun. (2022), 13: 59.
8. Nichols, M.D., DeAngelis, K., Keck, J.L. and Berger, J.M. Structure and function of an archaeal topoisomerase VI subunit with homology to the meiotic recombination factor Spo11. EMBO J. (1999), 18: 6177-6188.
9. Diane T. Takahashi, Daniele Gadelle, Keli Agama, Evgeny Kiselev, Hongliang Zhang, Emilie Yab, Stephanie Petrella, Patrick Forterre, Yves Pommier, Claudine Mayer. Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. Nat. Commun. (2022), 13, 59.
10. James J. Champoux. DNA TOPOISOMERASES: Structure, Function, and Mechanism. Annu. Rev. (2001), 70:369–413.